ODTX Odyssey Therapeutics, Inc.
$19.93▲ +2.21%
Healthcare
Other
Volume 74.8K
Avg Volume (10D) 222.9K
Key Metrics & Fundamentals
Market Cap
$957.81M
P/E Ratio
–
Div Yield
0.00%
52W Range
15.10 - 29.05
% vs 50 MA
-11.49%
% vs 200 MA
–%
RSI-14
48.8
MACD Histogram
+0.3200
Beta (1Y vs SPY)
1.19
Free Cash Flow
-$34.69M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$43.00M
COGS
–
Operating Exp
$46.74M
Operating Income
-$46.74M
EBIT
-$46.74M
Pretax Income
-$52.80M
Net Income
-$52.79M
EPS (Diluted)
-1.74
Price & Volume History
Loading chart…
Recent News
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
MarketBeat · Oct 25, 2026 12:02 PM ET
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
GlobeNewswire · Oct 20, 2026 7:00 AM ET
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
GlobeNewswire · Oct 12, 2026 8:00 AM ET
UBS Initiates Coverage on Odyssey Therapeutics With Buy Rating, $27 Price Target
MT Newswires · Oct 12, 2026 7:35 AM ET
Raymond James Initiates Odyssey Therapeutics at Outperform
MT Newswires · Oct 9, 2026 7:28 AM ET
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
GlobeNewswire · Oct 6, 2026 8:00 AM ET
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
GlobeNewswire · Sep 16, 2026 8:00 AM ET
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
Insider Monkey · Sep 13, 2026 10:44 PM ET
HC Wainwright Initiates Odyssey Therapeutics at Buy With $44 Price Target
MT Newswires · Aug 27, 2026 7:33 AM ET
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire · Aug 26, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2025
See ODTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.